None

Alnylam's CEO Presents at 31st Annual J.P. Morgan Healthcare Conference (Transcript)

Alnylam Pharmaceuticals, Inc. (ALNY) 31st Annual J.P. Morgan Healthcare Conference Transcript January 9, 2013 11:00 AM ET Executives John Maraganore - Chief Executive Officer Barry Greene - Presid...

Alnylam Pharmaceuticals prices public offering of common stock for $161 million

Alnylam Pharmaceuticals announced the pricing of an underwritten registered public offering of 8,000,000 shares of its common stock at a public offering price of $20.13 per share. All of the shares in...

Alnylam Pharmaceuticals' Management Presents at J.P. Morgan SMid Cap Conference (Transcript)

Alnylam Pharmaceuticals, Inc. (ALNY) J.P. Morgan SMid Cap Conference November 29, 2012, 11:00 am ET Executives Mike Mason - VP, Finance and Treasury Analysts Anupam Rama - JPMorgan Presenta...

Alnylam Pharmaceuticals Management Presents at J.P. Morgan SMid Cap Conference - Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) J.P. Morgan SMid Cap Conference November 29, 2012, 11:00 am ET Executives Mike Mason - VP, Finance and Treasury Analysts Anupam Rama - JPMorgan Presenta...

Isis Pharma gets $1.1M payment from Alnylam

Isis Pharmaceuticals Inc. said Tuesday that it will get $1.1 million from Alnylam Pharmaceuticals Inc. as part of Alnylam's new collaboration with Genzyme.Alnylam and Genzyme announced Monday that th...

Alnylam Gets $25M From Medicines Co. for Cholesterol Drug

Cambridge, MA-based Alnylam Pharmaceuticals has found a partner willing to help it go up against against some formidable competitors with a new class of cholesterol-lowering drugs. Alnylam (NASDAQ: AL...

Figure: Alnylam chronicles

IP armamentarium Alnylam chronicles With so many of its early years devoted to figuring out RNAi delivery, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) had to depend on its investors, who weren't always...

Tekmira-Alnylam Lawsuit Centers on Drug Carrier Particles

Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ:ALNY) has been working with Tekmira Pharmaceuticals (TSE:TKM) of Vancouver, BC, since at least 2006 on getting its gene-silencing drugs into cells t...

Unique Gene-Silencing and Structural Properties of 2'-Fluoro-Modified siRNAs.

Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo.

Special (lipid) delivery: The role of the ionizable lipid pK(a) in the in vivo delivery of siRNA by lipid nanoparticles has been studied with a large number of head group modifications to the lipids...

An immobilized and reusable Cu(i) catalyst for metal ion-free conjugation of ligands to fully deprotected oligonucleotides through click reaction.

Chelation of Cu(i) ions to an immobilized hydrophilic tris(triazolylmethyl)amine chelator on a solid support allowed synthesis of RNA oligonucleotide conjugates from completely deprotected alkyne-olig...

Microsatellite markers as a rapid approach for autozygosity mapping in Hermansky-Pudlak syndrome: Identification of the second HPS7 mutation in a patient presenting late in life.

Weismann Versus Morgan Revisited: Clashing Interpretations on Animal Regeneration.

This paper has three principal aims: first, through a detailed analysis of the hypotheses and assumptions underlying Weismann's and Morgan's disagreement on the nature of animal regeneration, it seeks...